<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-04-14 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use." This guidance is intended to assist abbreviated new drug application (ANDA) applicants that reference a drug product intended for parenteral, ophthalmic, or otic use in seeking approval of a drug that is qualitatively (Q1) different or quantitativel...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-08012</p>
    <p><strong>Publication Date:</strong> 2022-04-14</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/04/14/2022-08012/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral">https://www.federalregister.gov/documents/2022/04/14/2022-08012/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-08012</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
